SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex Inc. ($CETX) is trending as traders discuss its potential for a short squeeze, drawing comparisons to recent runners like $SMX and $TWG. Community members are actively analyzing the stock's low float and high trading volume, with some expressing concerns about potential manipulation and dilution. Bullish investors are urging others to hold firm, anticipating a significant move in after-hours trading.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune ($ALT) is trending as investors anticipate upcoming 48-week data, with some expecting positive results and a potential buyout. Discussions revolve around the significance of the data, especially regarding fibrosis improvement, and the impact of the recent FDA qualification of PathAI's AI-based histology tool for MASH trials. The community is also actively debating the company's leadership change and potential catalysts.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to significant price action and high trading volume, reminiscent of other recent low-float runners. Community discussions revolve around its potential for continued gains, with some cautioning about pump-and-dump schemes and the volatility associated with Chinese stocks. Traders are actively watching for breakout opportunities and setting price targets, while also weighing the risks of entering the stock at its current levels.

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

XCUR is trending following positive Phase 2 trial results for its drug burixafor, used in multiple myeloma treatment, driving excitement among investors. The community is discussing the potential for a significant squeeze due to the stock's small float and signs of short-term breakout potential, with some mentioning past runs and comparing it to other low-float stocks.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending as it's set to join the S&P 500, driving a surge in price and triggering debate about its valuation. The community is discussing whether this inclusion is justified, given concerns about the company's financials and business model, with some viewing it as a potential short opportunity while others anticipate further gains due to index fund buying.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

NFLX is trending amidst uncertainty surrounding its deal with Warner Bros. Discovery, with investors weighing the potential benefits and risks after a competing offer emerged. Community discussions revolve around the likelihood of the deal closing, potential regulatory hurdles involving Trump, and whether NFLX will increase its offer or walk away, possibly collecting a termination fee.

SAIHEAT Ltd. engages in the operation of cryptocurrency mining. It operates Bitcoin for its own account and provides full suite of services, purchase of mining machines, hosting service, and mining pool. The company was founded by Risheng Li on February 2, 2021, and is headquartered in Singapore.

SAIHEAT Ltd. - Ordinary Shares - Class A

SAIHEAT Ltd

SAIH is trending due to its low float and potential for a squeeze, with traders drawing comparisons to recent high-flying stocks like $CETX and $TWG. Community members are highlighting the stock's potential for a breakout, citing stacked bids and anticipation of shorts covering. Some are pointing to its potential in nuclear power and AI as additional catalysts, while others are mentioning its prior moves in after-hours trading.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences (WVE) is trending due to a significant surge following positive Phase 1 data for its obesity drug, WVE-007. The community is discussing the potential for a large offering given the stock's massive gains and the company's need for funding, with some traders anticipating a pullback while others remain bullish on the drug's prospects.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community discusses its potential breakout against Bitcoin and anticipates a broader altcoin rally. Bullish sentiment seems to be driven by Litecoin's perceived undervaluation and historical role as digital silver, while some traders eye specific price levels as key targets. The conversation also includes potential integration with new financial infrastructures.

AlphaTime Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on September 15, 2021 and is headquartered in New York, NY.

AlphaTime Acquisition Corp

ATMC is trending due to its merger with HCYC, an Asian insurance brokerage, which is nearing completion. This SPAC's low float is fueling speculation and significant after-hours movement, with community members actively discussing potential ROI and warrant values post-merger. Some traders are pointing to previous low float runners, advising caution due to the high volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Terns shares jumped after new Phase 1 data showed strong response rates and a continued favorable safety profile for TERN-701.</li><li>Updated results showed high 24-week molecular responses across doses with no loss of response and no dose-limiting toxicities.</li><li>The company said the findings support Phase 2 advancement, with deep responses seen even in patients previously failing multiple therapies.</li></ul>Terns Pharmaceuticals (TERN) shares jumped over 40% on Monday after the company reported additional positive Phase 1 results for its investigational chronic myeloid leukemia (CML) therapy TERN-701 at the 67th American Society of Hematology Annual Meeting.The biotech company said updated data from the ongoing CARDINAL trial showed a 64% major molecular response (MMR) rate by 24 weeks across all efficacy-evaluable patients, with a 75% MMR rate among those receiving doses above 320 mg once daily.&nbsp;The company said the treatment continued to show an encouraging safety and tolerability profile with longer exposure.<h2 class="st-heading-2">Terns Sets Phase 2 Doses&nbsp;</h2>CEO Amy Burroughs said the higher MMR rate at doses of 320 mg and 500 mg supports selection of those levels as recommended Phase 2 doses. She said study enrollment has surpassed 85 patients, enabling further progression into dose-expansion and pivotal studies.Chief Medical Officer Emil Kuriakose said the data include response achievements in patients who had previously experienced lack of efficacy on drugs such as Asciminib, Ponatinib and other tyrosine kinase inhibitors. He said the updated findings show deep molecular responses (DMR) at 24 weeks and a continued favorable safety profile across doses.<h2 class="st-heading-2">Strong 24-Week Response Rates</h2>As of the Sept. 13 cutoff, 63 patients had been enrolled across doses ranging from 160 mg to 500 mg. Among 38 efficacy-evaluable patients, the overall MMR rate by 24 weeks was 74%. No patients had lost MMR at the time of analysis.The company said the study population reflected heavily pretreated, refractory disease, including a median of three prior tyrosine kinase inhibitors (TKIs) and high rates of lack of efficacy to previous therapy.Safety data showed that 87% of patients remained on treatment, with no dose-limiting toxicities observed and no maximum tolerated dose reached. Most treatment-emergent adverse events were low grade, and rates of cytopenias were generally under 10%.<h2 class="st-heading-2">Responses At Higher Doses</h2>Among patients treated at doses of 320 mg or higher, the company reported an 80% overall MMR rate by 24 weeks in the efficacy-evaluable population. Deep molecular responses were observed across a wide range of baseline transcript levels.<h2 class="st-heading-2">Stocktwits Traders Cheer Momentum</h2>On Stocktwits, retail sentiment for Terns was ‘bullish’ amid ‘low’ message volume.<figure class="image"><img style="aspect-ratio:984/147;" src="https://news.stocktwits-cdn.com/terns_ss_png_43b9b42eb3.webp" alt="terns ss.png" width="984" height="147"><figcaption>TERN sentiment and message volume as of December 8| Source: Stocktwits</figcaption></figure>One user said, “congrats!&nbsp; Bio market is starting to have some movers. Good to see!”<stembedurl>https://stocktwits.com/Hard6and8/message/638531110</stembedurl>Another user urged investors to “buy it up.”<stembedurl>https://stocktwits.com/Whiskeyunderthebed/message/638530725</stembedurl><a href="https://stocktwits.com/symbol/TERN">Tern’s stock</a> has surged 620% so far this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tern's stock (TERN) has surged 489% so far in 2025. (Photo credit: Getty Images)

Terns Pharmaceuticals Stock Soars After Leukemia Drug Delivers Big Early Responses In Tough-To-Treat Patients

New Phase 1 data showed strong response rates and a favorable safety profile for its experimental leukemia drug TERN-701.

Equity

Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up - Time to Buy?

Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up - Should You Buy...

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 5.5% - Here's Why

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 5.5% - Still a Buy...

Terns Pharmaceuticals (NASDAQ:TERN) Reaches New 1-Year High - Still a Buy?

Terns Pharmaceuticals (NASDAQ:TERN) Sets New 52-Week High - Should You Buy...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Rating of "Moderate Buy" from Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, MarketBeat.com reports...

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 5.7% - Time to Sell?

Terns Pharmaceuticals (NASDAQ:TERN) Shares Down 5.7% - Time to Sell...

DLD Asset Management LP Buys New Position in Terns Pharmaceuticals, Inc. $TERN

DLD Asset Management LP purchased a new position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the...

Terns Pharmaceuticals (NASDAQ:TERN) Sets New 1-Year High - Should You Buy?

Terns Pharmaceuticals (NASDAQ:TERN) Reaches New 12-Month High - What's Next...

Terns Pharmaceuticals (NASDAQ:TERN) Price Target Raised to $35.00 at Truist Financial

Truist Financial increased their price objective on shares of Terns Pharmaceuticals from $28.00 to $35.00 and gave the stock a "buy" rating in a research report on Wednesday...

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says

BMO Capital Markets increased their price target on Terns Pharmaceuticals from $22.00 to $30.00 and gave the company an "outperform" rating in a research report on Tuesday...

https://files.quartr.com/streams/2025-12-08/cf555084-1e06-4102-8b66-6d881946e101/2/live_transcript.jsonl?ref=U3RvY2t0d2l0cw==

🚨 LIVE Earnings on Polymarket. 
Trading earnings just got much simpler: Will your favorite stock beat earnings – Yes or No?

Polymarket

Terns Pharmaceuticals Inc

Status Update

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

25bps decrease

No change

50+ bps decrease

25+ bps increase

Fed decision in December? *Powered by Polymarket

Stocktwits

Stocktwits Polls

Terns Pharmaceuticals is trending following positive Phase 1 clinical data for TERN-701, which is being developed for chronic myeloid leukemia, with the community noting the potential to disrupt the CML treatment landscape. Bullish investors are focused on the drug's efficacy and safety profile, while others discuss potential peak sales and acquisition scenarios. However, some traders are wary of the high valuation based on early-stage data and potential for a future offering.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.30	--	--	N/A
Q3 '25	-$0.30	-$0.27	9.02%	BEAT
Q2 '25	-$0.29	-$0.26	10.45%	BEAT
Q1 '25	-$0.29	-$0.26	11.54%	BEAT
Q4 '24	-$0.31	-$0.24	21.61%	BEAT

TERN
Terns Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest TERN News

TERNTerns Pharmaceuticals Inc